Trial Profile
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Oct 2021
Price :
$35
*
At a glance
- Drugs AGS 62P1 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Agensys; Astellas Pharma
- 23 Mar 2021 Status changed from active, no longer recruiting to discontinued.
- 23 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 10 Oct 2018 Planned number of patients changed from 150 to 60.